Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery

Model scores of the 29,894 trials active now.

Model score 28% for any early termination, 17% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (607 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-06-23. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerfailurepainheartto determine
  Phrases that lowered it: participantseffect ofthe effectallergicinvestigating the
• Sponsor's past termination rate: 22.6% (raises risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 67.9% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 12.7% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Blinding: triple (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 29 (lowers risk) · Sponsor's track record
• Primary purpose: supportive care (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 208 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 109307 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 764954 (lowers risk) · Drug's FDA history
• Keywords listed: 2 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery NCT03682367 · started 2018 · scored riskier than 73% of active trials terminated
• Local Infusion of Ropivacaine for Post-Op Pain Control After Osseocutaneous Free Flaps NCT03349034 · started 2017 · scored riskier than 72% of active trials completed
• Opioid Therapy vs Multimodal Analgesia in Head and Neck Cancer NCT04221165 · started 2020 · scored riskier than 88% of active trials completed
• Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head & Neck Cancer NCT01653327 · started 2010 · scored riskier than 89% of active trials completed
• The Effect of Opioid-Free Anesthesia in TMJ Surgery NCT04724759 · started 2021 · scored riskier than 63% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.